Curanex Pharmaceuticals Inc
Close on Oct 19, 2026
- Market cap
- $139.55M
- P/E (TTM)
- –
- Dividend yield
- –
About Curanex Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Curanex Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing botanical medicines for patients with inflammatory diseases. The company's lead drug candidate is Phyto-N, a proprietary botanical extract derived from a medicinal plant used in traditional Chinese medicine. Curanex is advancing a development pipeline targeting six core indications: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, with its primary development focus on ulcerative colitis.
The company operates as a single corporate entity without subsidiaries and conducts its nonclinical research across partner academic and research institutions. Its planned Phase 1 clinical development is scheduled to take place in Australia following regulatory clearances. Curanex Pharmaceuticals is incorporated in Nevada and maintains its principal executive offices in Jericho, New York.
Summary of the business section of Curanex Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Curanex Pharmaceuticals Inc
- Founded
- 2018
- Headquarters
- Jericho, NY
- Address
- 2 Jericho Plaza,, Suite101b 11753
- Phone
- (718) 673-6078
- Website
- curanexpharma.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Kreit & Chiu CPA LLP, Los Angeles, California
Stock & identifiers
- Ticker
- CURX
- Exchange
- Nasdaq
- IPO date
- Aug 26, 2025
- Shares outstanding
- 31M, Aug 14, 2026
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-20 reverse, Aug 20, 2026
- SEC CIK
- 2025942
- EIN
- 83-0741390
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jun Liu | CEO and President, Director | 10,524,560 |
| Huijuan Zhong | Chief Science Officer, Director | – |
| Ning Zhang | Chief Technology Officer | – |
| Dian Ying Jing | Secretary | 4,651,000 |
| Liqin Xie | Chief Operating Officer | – |
| Xiaohui Hao | Director | – |
| Yong Yan | Director | – |
| Helen Hong Hsu | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 17, 2025 | Late filing | Notification of late filing |
| Nov 6, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 26, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 25, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |